280. 巨大動静脈奇形（頚部顔面又は四肢病変） Huge arteriovenous malformation with cervicofacial or limb lesion Clinical trials / Disease details

臨床試験数 : 25 / 薬物数 : 29 - (DrugBank : 15) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 153

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001530-33-FR (EUCTR)	29/06/2019	01/04/2019	TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN	TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN - TOPGUN	Lingual microcystic lymphatic malformations (LMLM) in children and adults MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: RAPAMUNE Product Name: Sirolimus 1mg/mL Product Code: L04AA10	CHRU TOURS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France
2	EUCTR2018-001359-11-FR (EUCTR)	22/02/2019	23/07/2018	0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial	0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICAL	Cutaneous microcystic lymphatic malformations (CMLM) in children and adults MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Product Name: Sirolimus 0,1% crème INN or Proposed INN: SIROLIMUS	CHRU TOURS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	55	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France
3	JPRN-UMIN000030522	2017/11/14	22/12/2017	A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies		Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations	Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.	Gifu University	NULL	Recruiting	Not applicable	Not applicable	Male and Female	50	Not selected	Japan
4	NCT02042326 (ClinicalTrials.gov)	September 12, 2014	20/1/2014	Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations	Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations	Arteriovenous Malformations	Drug: Sirolimus	Centre Hospitalier Universitaire, Amiens	NULL	Recruiting	2 Years	N/A	All	50	Phase 2	Belgium;France